Bone marrow transplantation may increase cancer resistance in patients
Key points
- Bone marrow transplantation with genetically modified cells may prolong the period of cancer-free survival, suggests a study led by Dr.
- Bone marrow, a spongy tissue inside bones, contains stem cells that produce blood cells, including leukocytes, erythrocytes and platelets.
- Par-4 (also known as PAWR) is a tumor suppressor protein that selectively induces apoptosis in cancer cells, but not normal cells.
- After transplantation, the researchers discovered the expression of cancer-killer SAC-GFP activity in bone marrow cells of the recipient mice, implying the successful transfer and colonization of the anti-cancer tissue from the donors.
Bone marrow transplantation with genetically modified cells may prolong the period of cancer-free survival, suggests a study led by Dr. Vivek Rangnekar, associate director of translational research for the Markey Cancer Center at the University of Kentucky.
Bone marrow, a spongy tissue inside bones, contains stem cells that produce blood cells, including leukocytes, erythrocytes and platelets. In the cover story of the July issue of Cancer Biology & Therapy, Rangnekar and his team explore the transfer of bone marrow from Par-4/SAC-transgenic donor mice to control mice as a means of transferring anti-cancer potential.
Par-4 (also known as PAWR) is a tumor suppressor protein that selectively induces apoptosis in cancer cells, but not normal cells. This function of Par-4 is mediated by its central core domain, SAC. SAC-transgenic mice are resistant to the growth of spontaneous and inducible tumors.
After transplantation, the researchers discovered the expression of cancer-killer SAC-GFP activity in bone marrow cells of the recipient mice, implying the successful transfer and colonization of the anti-cancer tissue from the donors. In addition, soluble Par-4 or SAC protein injected into mice inhibited the growth of metastatic tumors.
Rangnekar, the Alfred Cohen Endowed Chair of Oncology Research at Markey, says the study shows promise for treating both primary and metastatic tumors.
"We are excited by the findings of this study as they indicate that secreted Par-4 is systemically active in mice," Rangnekar said. "Optimization of the bone marrow transplantation procedure using stem cells that are genetically modified to systemically secrete potent protein payloads of Par-4/SAC killer activity may offer a new approach to treat not only primary tumors but also metastatic tumors of diverse origin."
###
Contact: Allison Perry
[email protected]
859-323-2399
University of Kentucky
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsBPA increases risk of cancer in human prostate tissue
Fetal exposure to a commonly used plasticizer found in products such as water bottles, soup can liners and paper receipts, can increase the risk for prostate cancer later in life, according to a study from the…
8 January 2014
NewsProtein in prostate biopsies signals increased cancer risk
Researchers from Weill Cornell Medical College have shown that the presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. The…
4 December 2013
News3D mammography increases cancer detection and reduces call-back rates, Penn study finds
Compared to traditional mammography, 3D mammography—known as digital breast tomosynthesis—found 22 percent more breast cancers and led to fewer call backs in a large screening study at the Hospital of the University of…
